BOSTON--(BUSINESS WIRE)--Sep. 22, 2017--
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing
drugs to treat cancer, today announced that the company will present at
the Cantor Fitzgerald Global Healthcare Conference on Monday, September
25th at 8:35 a.m. ET at the InterContinental New York Barclay
Hotel in New York.
A live audio webcast of the presentation will be available on the
company’s website at www.verastem.com.
An archived presentation will be available for 90 days.
About Verastem, Inc.
Verastem, Inc. (NASDAQ:VSTM) is a biopharmaceutical company focused on
discovering and developing drugs to improve outcomes for patients with
cancer. Verastem is currently developing duvelisib, a dual inhibitor of
PI3K-delta and PI3K-gamma, which has successfully met the primary
endpoints in both a Phase 2 study in double-refractory iNHL and a Phase
3 clinical trial in patients with relapsed/refractory CLL/SLL. In
addition, Verastem is developing the FAK inhibitor, defactinib, which is
currently being evaluated in three separate clinical collaborations in
combination with immunotherapeutic agents for the treatment of several
different cancer types, including pancreatic, ovarian, non-small cell
lung cancer, and mesothelioma. Verastem’s product candidates seek to
treat cancer by modulating the local tumor microenvironment, enhancing
anti-tumor immunity and reducing cancer stem cells. For more
information, please visit www.verastem.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170922005297/en/
Source: Verastem, Inc.
Verastem, Inc.
Brian Sullivan, 781-292-4214
Director,
Corporate Development
bsullivan@verastem.com
